Allarity Therapeutics, Inc. (ALLR)

NCM – Real vaqt narxi. Valyuta: USD

1.52

-0.16 (-9.52%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that CEO Thomas Jensen has been invited to participate as a speaker at Precision Medicine Forum Europe 2026, taking place May 11–12, 2026, in Stockholm, Sweden.

05.05.2026

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancer Supports accelerating stenoparib toward FDA approval following FDA Fast Track designation All manufacturing-related payments completed; no additional cash outlays for manufacturing are anticipated TARPON SPRINGS, Fla., MAY 5, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that its active pharmaceutical ingredient (API) manufacturing campaign for stenoparib is progressing in line with the planned timeline for completion no later than the third quarter of 2026 at its world-class contract development and manufacturing organization (CDMO).

27.04.2026

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

TARPON SPRINGS, Fla., April 27, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company's DRP® companion diagnostic specific to stenoparib.

31.03.2026

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028 Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancer Durable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implemented Expansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced financial results for the year ended December 31, 2025.

06.03.2026

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Structured as Non-Convertible Debt Financing TARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has closed a $20 million non-convertible debt financing with Streeterville Capital.

18.02.2026

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung Cancer Trial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA sites nationwide Relapsed SCLC remains an area of high unmet need without effective treatment options TARPON SPRINGS, Fla., February 18, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the first patients have been dosed with stenoparib and temozolomide in the VA-funded investigator-initiated Phase 2 trial for the treatment of relapsed small cell lung cancer (SCLC).

03.02.2026

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the US TARPON SPRINGS, Fla., February 3, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that enrollment is now open for its new Phase 2 clinical trial evaluating the combination of stenoparib and temozolomide for the treatment of recurrent small cell lung cancer (SCLC).

Videolar

No Data

There is no data to display

Press-relizlar

05.05.2026

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

27.04.2026

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

31.03.2026

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

06.03.2026

Allarity Therapeutics, Inc. (ALLR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Allarity Therapeutics, Inc. (ALLR)

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Videolar

No Data

Press-relizlar

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Videolar

No Data

Press-relizlar

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Search stocks

Allarity Therapeutics, Inc. (ALLR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Allarity Therapeutics, Inc. (ALLR)

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Videolar

No Data

Press-relizlar

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

Videolar

No Data

Press-relizlar

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization